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Introduction: Acceleration of radiotherapy in 5 fractions for breast cancer can reduce the burden of
treatment. We report on acute toxicity after whole-breast irradiation with a simultaneous integrated
boost in 5 fractions over 10e12 days.
Material and methods: Acute toxicity and health-related quality of life (HRQoL) of 200 patients, ran-
domized between a 15- or 5-fractions schedule, were collected, using the CTCAE toxicity scoring system,
the Multidimensional Fatigue Inventory, EORTC QLQ-C30 and BR23 and the BREAST-Q questionnaire. The
prescribed dose to the breast was either 15*2.67 Gy (40.05 Gy) or 5*5.7 Gy (28.5 Gy). 90% of patients
received a SIB to a cumulative dose of 46.8 Gy (15*3.12 Gy) or 31 Gy (5*6.2 Gy).
Results: Physician-assessed toxicity was lower for the 5-fractions group. A significant difference was
observed for breast pain (p ¼ 0.002), fatigue (p < 0.0001), breast edema (p ¼ 0.001) and dermatitis
(p ¼ 0.003). Patients treated in 5 fractions reported better mean HRQoL scores for breast symptoms
(p ¼ 0.001) and physical well-being (p ¼ 0.001). A clinically important deterioration in HRQoL of 10
points or more was also less frequently observed in the latter group for physical functioning (p ¼ 0.0005),
social functioning (p ¼ 0.0007), fatigue (p ¼ 0.003), breast symptoms (p ¼ 0.0002) and physical well-
being (p ¼ 0.002).
Conclusion: In this single institute study, acute toxicity of accelerated breast radiotherapy in 5 fractions
over 10e12 days seems to compare favourably to hypofractionated breast radiotherapy in 15 fractions.
Less breast edema, dermatitis, desquamation, breast pain and fatigue are seen. Social and physical
functioning are also less disturbed and patients have a better future perspective.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction






. De Neve), liv.veldeman@
Ltd. This is an open access article u(BCS) for breast cancer reduces the locoregional recurrence rate and
improves overall survival [1,2]. Hypofractionation with 15 or 16
fractions instead of 25 fractions has become the standard of care for
whole breast irradiationwithout nodal RT. Equal or less toxicitywas
seen with the hypofractionated schedules in the Canadian hypo-
fractionation trial and the UK START trials [3e5]. In the START-B
trial, reducing the overall treatment time from 5 weeks to 3
weeks led to improved disease free survival and overall survival
rates, probably due to less distant relapses [3].
Acceleration in 5 fractions over 5 weeks is feasible in the elderly
populationwithout an increase in relapse rates andwith acceptable
toxicity [6e9]. The UK FAST trial randomized between a 5-fractionsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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study, only patients aged 50 years or older with node negative
breast cancer were included. None of the patients received a boost,
i.e. a higher dose to the tumour bed [10]. No differences were seen
for late toxicity, locoregional or distant relapse, nor mortality [9].
From a radiobiological point of view as well as from a patient’s
point of view, it is of interest to further shorten the overall treat-
ment time. At Ghent University Hospital, a hypofractionation
schedule of 5 fractions of 5.7 Gy over 10e12 days was introduced in
patients agzed 65 yeats or older [11]. We chose the same pre-
scription dose as the FAST trial to not compromise on tumour
control but treatment on consecutive days was not allowed to allow
repair of normal tissues in-between fractions. A simultaneous in-
tegrated boost (SIB) of 5 times 6.5 Gy was allowed. Using an alpha/
beta of 4.6 Gy, this schedule was judged to be equivalent to the then
standard fractionation schedule used at Ghent University Hospital:
15 fractions of 2.67 Gy with a sequential boost (SEB) of 4 times
2.5 Gy. Feasibility of this schedule was tested in the HAI-5 trial [11].
Matched-case analyses with patients treated in 15 fractions showed
less acute [12] and less late [13] toxicity for 5 fractions except for
fibrosis outside the tumour bed. Better health-related quality of life
(HRQoL) was observed in the group treated in 5 fractions, both
immediately after RT and after 1 year [14].
More recently, the FAST Forward trial was published, further
limiting overall treatment time to 5 fractions of 5.2 Gy in 1 week
[15]. Again, this schedule showed equivalent results for late toxicity,
relapse and survival at 5 years after irradiation as a 15-fractions
schedule of 2.67 Gy over 3 weeks. Only one fourth of patients
received a boost, which was given sequentially. Such SEB of 5e8
fractions at least doubles the treatment time and increases the
number of hospital visits, which is not the case with the HAI5
schedule using a SIB.
After showing feasibility of the HAI5 schedule in older patients,
the YO-HAI5 (Young-Old Highly Accelerated Irradiation in 5 frac-
tions) randomized controlled trial was introduced at Ghent Uni-
versity Hospital in patients of 18 years or older, receiving whole
breast irradiation (WBI) ± SIB after BCS. Taken into account the
reduced overall treatment time and fearing increased late toxicity,
the SIB dose was reduced to 5 fractions of 6.2 Gy.
In the present interim analysis of the YO-HAI5 trial, physician-
assessed acute toxicity and patient-related outcomes for HRQoL
are reported in the first 200 randomized patients.
2. Materials and methods
2.1. Study design and -population
The YO-HAI5 study (NCT03677427, www.clinicaltrials.gov) is a
randomized controlled trial in 400 breast cancer patients aged 18
years or older treated with BCS, requiring adjuvant WBI ± SIB ac-
cording to the multidisciplinary tumour board. Informed consent
was obtained, signed and dated for all patients before specific
protocol procedures. Exclusion criteria are: lymph node metastases
or distant metastases; bilateral breast irradiation; a history of ra-
diation treatment to the same region, including radiation treatment
to the contralateral breast; a life expectancy of less than 2 years;
planned reconstructive surgery; conditions making toxicity evalu-
ation difficult (e.g. skin disorders); inability to respect constraints
on organs at risks and patients unlikely to comply with the pro-
tocol, e.g. unable to return for follow-up visits or unlikely to com-
plete the study. The study protocol was approved by the hospital’s
ethics board. The primary endpoint of the trial is breast retraction 2
years after RT. Secondary endpoints are acute breast toxicity, late
toxicities other than breast retraction, fatigue, cosmesis, HRQoL,
cost effectiveness, locoregional and distant tumour control and106dose/volume parameters of target and organs of risk. In the present
sub-analysis, acute toxicity and HRQoL are reported for the first 200
randomized patients. SAS Power and Sample Size software was
used for the sample size calculation with a ¼ 0.05 and b ¼ 0.8.
Dermatitis was the toxicity of main interest for acute toxicity, the
sub-analysis was conducted in at least 170 patients, based on the
matched-case analysis [12].
2.2. Randomization and radiotherapy
A computer-generated simple randomizationwas used to assign
patients to a 15- or 5-fractions RT schedule. In the standard arm,
treatment consists of 15 fractions of 2.67 Gy to the whole breast
with a SIB to the tumour bed of 15*3.12 Gy, if indicated. RT was
delivered 5 days a week, not in the weekend. In the experimental
arm, 5 fractions of 5.7 Gy were delivered with a SIB of 5*6.2 Gy. RT
was delivered onweek-days with at least 40 h between consecutive
treatment fractions, leading to an overall treatment time of 10e12
days.
All patients underwent computed tomography (CT) imaging
without administration of iodine contrast for treatment planning. If
possible, patients were treated in prone position, with supine po-
sition as alternative if prone position proved impossible. Left sided
breast cancer patients were treated with deep inspiration breath
hold to reduce heart dose when dose constraints were not achieved
in free breathing. The clinical target volume (CTV) for WBI was
delineated as proposed by the ESTRO guidelines [16,17] with the aid
of a radio-opaque wire placed around the breast contour. Target
objectives and dose constraints were added in appendix.
2.3. Assessment
Both physician-assessed toxicity and patient-reported outcome
are evaluated. Physician-assessed acute toxicity is scored at base-
line and at 2e4 weeks after treatment stop using the Common
Terminology Criteria for Adverse Events (CTCAE) version 4.03
toxicity scoring system. Fatigue is measured by the Multidimen-
sional Fatigue Inventory (MFI-206).
HRQoL, collected at the same moments of physician-assessed
toxicity, is evaluated using the European Organisation for
Research and Treatment of Cancer (EORTC) 30-item Quality of Life
Questionnaire (QLQ-C30), the breast cancer specific module of the
EORTC QLQ (QLQ-BR23) and the BREAST-Q questionnaire [18e20].
From the QLQ-C30 and QLQ-BR23 questionnaires, only the items
evaluating RT-related HRQoL were withheld: the global health
scale, 2 functional scales (physical and social functioning) and 2
symptom scales (fatigue and pain) for QLQ-C30, and 2 symptom
scales (arm- and breast symptoms) and one functional scale (future
perspective) for QLQ-BR23. The questionnaires can be found in
appendix B.
Study data were collected and managed anonymously using
REDCap electronic data capture tools hosted at Ghent University
Hospital.
2.4. Statistical analysis
The statistical package SPSS version 26 was used to analyse the
data. RT-related toxicity was defined as any baseline toxicity that
deteriorated during or after RT and any toxicity that arose during or
after RT and was not present at baseline. Mild toxicity (grade 1), as
well as moderate (grade 2) and marked (grade 3 or more) toxicity
was taken into account. Results were analysed for both effective
treatment and intention to treat (Table 2). A clinically relevant
deterioration of HRQoL was defined as a difference in score of 10
points or more between baseline and 2e4 weeks after RT [21].
Table 1
Patient, tumour and treatment characteristics for effective treatment.
5-fractions schedule (N ¼ 106) 15-fractions schedule (N ¼ 94) Sign.
Patient characteristics
Age, years p ¼ 0.3
Median 59 62
Range 37e83 26e84
<40 3 (2.8%) 5 (5.3%)
40-49 10 (9.4%) 10 (10.6%)
50-59 41 (38.7%) 25 (26.6%)
60-69 34 (32.1%) 40 (42.6%)
70-79 16 (15.1%) 11 (11.7%)
80 2 (1.9%) 3 (2.8%)
Body Mass Index (BMI) p ¼ 0.05
Median 25.0 25.6
<20 6 (5.7%) 12 (12.8%)
20-25 47 (44.3%) 28 (29.8%)
>25 53 (50%) 54 (57.4%)
Breast volume (mean) 472.30 C C 489.77 C C p ¼ 0.9
Smoking behaviour p ¼ 0.6
Current 9 (8.5%) 12 (12.8%)
Former 26 (24.5%) 24 (25.5%)
Never 71 (67.0%) 58 (61.7%)
Alcohol use p ¼ 0.4
Current 72 (67.9%) 71 (75.5%)
Former 6 (5.7%) 6 (6.4%)
Never 28 (26.4%) 17 (18.1%)
Tumour characteristics
Tumour side p ¼ 0.5
Left 53 (50.0%) 42 (44.7%)
Right 53 (50.0%) 52 (55.3%)
Tumour location p ¼ 0.6
Lower-inner quadrant 12 (12%) 12 (13%)
Lower-outer quadrant 12 (12%) 17 (18%)
Upper-inner quadrant 18 (17%) 9 (9%)
Upper-outer quadrant 47 (44%) 42 (44%)
Central portion of the breast 17 (16%) 16 (17%)
Histological grade p ¼ 0.6
Poor 23 (22%) 21 (22%)
Moderate 65 (61%) 52 (55%)
Well 18 (17%) 21 (22%)
Histological type p ¼ 0.6
DCIS 5 (5%) 8 (8%)
Infiltrating lobular 10 (10%) 8 (8%)
Infiltrating ductal 86 (81%) 72 (77%)
Tubular 1 (1%) 3 (3%)
Other 4 (4%) 3 (3%)
Pathological tumour size p ¼ 0.5
Mean 15 mm (SD 6.2) 11 mm (SD 7.7)
Range 1e26 mm 1e35 mm
Ki 67 p ¼ 0.9
<20% 53 (50.0%) 48 (51.1%)
20% 41 (38.7%) 34 (36.2%)
Unknown 12 (11.3%) 12 (12.8%)
HER-2 Immunohistochemistry p ¼ 0.5
Negative 43 (40.6%) 34 (36.2%)
Positive: 1þ 21 (19.8%) 28 (29.8%)
Positive: 2þ 17 (16.0%) 15 (16.0%)
Positive: 3þ 7 (6.6%) 3 (3.2%)
Unknown 18 (17.0%) 14 (14.9%)
FISH/SISH/CISH p ¼ 0.3
Amplification 11 (10.4%) 6 (6.4%)
No amplification 41 (38.7%) 46 (48.9%)
Unknown 54 (50.9%) 42 (44.7%)
ER status p ¼ 0.7
Positive (>1%) 75 (70.8%) 63 (67.0%)
Negative (1%) 10 (9.4%) 12 (12.8%)
Unknown 21 (19.8%) 19 (20.2%)
PR status p ¼ 1.0
Positive (>5%) 69 (65.1%) 61 (64.9%)
Negative (5%) 16 (15.1%) 14 (14.9%)
Unknown 21 (19.8%) 19 (20.2%)
cTNM p ¼ 0.5
T1N0M0 90 (85%) 78 (83%)
T1N1M0 0 (0%) 1 (1%)
T2N0M0 11 (10%) 7 (7%)
(continued on next page)
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Table 1 (continued )
5-fractions schedule (N ¼ 106) 15-fractions schedule (N ¼ 94) Sign.
TisN0M0 5 (5%) 8 (9%)
pTNM p ¼ 0.5
T1N0M0 86 (81%) 77 (82%)
T1N1 (mi)M0 4 (4%) 2 (2%)
T2N0M0 11 (10%) 7 (7%)
TisN0M0 5 (5%) 8 (9%)
Treatment characteristics
Surgery
Type of surgery p ¼ 0.8
Segmentectomy/quadrantectomy 4 (3.8%) 3 (3.2%)
Wide local excision 102 (96.2%) 91 (96.8%)
Axillary surgery p ¼ 0.09
Axillary clearance 0 (0.0%) 1 (1.1%)
Sentinel node biopsy 94 (88.7%) 87 (92.6%)
No axillary surgery 12 (11,3%) 6 (6.4%)
Postoperative haematoma p ¼ 05
Yes 12 (11.3%) 11 (11.7%)
No 90 (84.9%) 83 (88.3%)
Unknown 4 (3.8%) 0 (0.0%)
Postoperative edema p ¼ 0.9
Yes 5 (4.7%) 4 (4.3%)
No 99 (93.4%) 88 (93.6%)
Unknown 2 (1.9%) 2 (2.1%)
Postoperative infection p ¼ 0.6
Yes 5 (4.7%) 6 (6.4%)
No 98 (92.5%) 87 (92.6%)
Unknown 3 (2.8%) 1 (1.1%)
Delayed wound healing p ¼ 0.2
Yes 0 (0.0%) 4 (4.3%)
No 103 (97.2%) 89 (94.7%)
Unknown 3 (2.8%) 1 (1.1%)
Chemotherapy
Neoadjuvant chemotherapy p ¼ 0.9
Yes 4 (3.8%) 4 (4.3%)
No 102 (96.2%) 90 (95.7%)
Adjuvant chemotherapy p ¼ 0.7
Yes 27 (25.5%) 22 (23.4%)
No 79 (74.5%) 72 (76.6%)
Hormone therapy p ¼ 0.9
Tamoxifen 48 (45.3%) 46 (48.9%)
Aromatase inhibitor 34 (32.1%) 29 (30.9%)
None 24 (22.6%) 19 (20.2)
Targeted therapy with trastuzumab p ¼ 0.3
Yes 11 (10.4%) 6 (6.4%)
No 95 (89.6%) 88 (93.6%)
Radiotherapy
Simultaneous integrated boost 95 (90.5%) 85 (90.4%) p ¼ 1.0
DIBH 2 (1.9%) 2 (2.1%) p ¼ 0.9
Position p ¼ 0.3
Prone 101 (95.3%) 91 (96.8%)
Supine 5 (4.7%) 3 (3.2%)
Overall treatment time (mean) 10.6 days (SD 0.8) 21.6 days (SD 1.3)
BMI: body mass index, DCIS: ductal carcinoma in situ, HER2: human epidermal growth factor receptor 2.
ER: estrogen receptor, PR: progesterone receptor, DIBH: deep inspiration breath hold.
Table 2
Physician-assessed acute toxicity for effective treatment and intention to treat.
Acute toxicity for effective treatment Acute toxicity for intention to treat
5-fraction schedule 15-fraction schedule 5-fraction schedule 15-fraction schedule
N 105 94 100 99
Breast pain 29 (27.6%) 47 (50.0%) 25 (25.0%) 51 (51.5%)
Fatigue 12 (11.4%) 37 (39.4%) 10 (10.0%) 39 (39.4%)
Breast edema 25 (23.8%) 44 (46.8%) 22 (22.0%) 47 (47.5%)
Grade 1 24 (22.2%) 40 (42.6%) 21 (21.0%) 43 (43.4%)
Grade 2 1 (1.0%) 4 (4.3%) 1 (1.0%) 4 (4.0%)
Dermatitis 61 (58.1%) 73 (77.7%) 57 (57.0%) 77 (77.8%)
Grade 1 44 (40.7%) 54 (57.4%) 44 (44.0%) 54 (54.5%)
Grade 2 17 (16.2%) 19 (20.2%) 13 (13.0%) 23 (23.2%)
Desquamation 15 (14.3%) 22 (23.4%) 12 (12.0%) 25 (25.3%)
Grade 1 12 (11.1%) 17 (18.1%) 11 (11.0%) 18 (18.2%)
Grade 2 3 (2.9%) 5 (5.3%) 1 (1.0%) 7 (7.1%)
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Fig. 1. Physician-assessed acute toxicity for effective treatment (Chi-squared test,*
Significance level: p < 0.05).
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tion of HRQoL between groups were analysed by performing a Chi-
square test with a significance level of p < 0.05. For HRQoL, sta-
tistical differences between baseline scores and scores after 2e4
weeks were evaluated with the Mann Whitney U test. Due to the
multiple tests for HRQoL, the Bonferroni correction was used to
avoid type I errors which leads to an adjusted p-value of p < 0.005.
3. Results
This sub-analysis of acute toxicity was performed on 200 pa-
tients, enrolled in the study between October 2017 and Februari
2020. Hundred and one patients were randomized to the 5-
fractions schedule and 99 to the 15-fractions schedule. Five pa-
tients randomized to 15 fractions were actually treated in 5 frac-
tions (protocol violation), which led to 106 patients effectively
treated in 5 fractions and 94 patients in 15 fractions. Data of acute
toxicity and HRQoL were lost in 1 case, since this patient refusedTable 3
Health-related quality of life.
Baseline 2e4 weeks after

















85.1 (16.4) 89.4 (11.6) p ¼ 0.1 87.0 (15.2)
Social functioning (SF) 85.1 (21.5) 84.4 (22.5) p ¼ 0.9 87.6 (20.4)
Future perspective
(BRFU)
60.6 (26.9) 63.1 (26.1) p ¼ 0.5 66.3 (22.9)
Symptom scales d
Fatigue (FA) 27.5 (19.6) 26.7 (22.6) p ¼ 0.5 28.7 (22.2)
Pain (PA) 18.7 (21.3) 15.4 (17.7) p ¼ 0.3 16.2 (18.1)
Arm symptoms (BRAS) 10.4 (13.7) 10.4 (15.4) p ¼ 0.7 9.6 (13.2)
Breast symptoms
(BRBS)




74.1 (16.8) 71.6 (17.7) p ¼ 0.5 72.9 (17.5)
Physical well-being d 14.2 (16.5) 12.6 (14.1) p ¼ 0.5 18.4 (18.8)
a Mann Whitney U test.
b Chi squared test, For botha andb Bonferroni correction is applied (significance level:
c Higher score indicates better functioning.
d Higher score indicates more symptoms.
e Significance.
109follow-up after randomization to the 5 fractions arm. Table 1 de-
scribes the patient, tumour and treatment characteristics for both
study groups.
All physician-assessed RT-related acute toxicities of any grade
are lower for the 5-fractions group, reaching statistical significance
for breast pain (p ¼ 0.002), fatigue (p < 0.0001), breast edema
(p ¼ 0.001) and dermatitis (p ¼ 0.003) but not for desquamation
(p ¼ 0.1) (Fig. 1).
Grade 2-toxicity is rare for breast edema and desquamation, but
not for dermatitis, with in both groups almost one fifth of patients
developing grade 2 toxicity (16% in the 5-fractions group and 20% in
the 15-fractions group). Grade 3 toxicity did not occur. As shown
in Table 2, the intention to treat analysis did not change the results.
In Table 3, patient reported outcomes are shown. No significant
differences between both groups are seen in HRQoL scores at
baseline. Two to four weeks after RT, patients treated in 5 fractions
experience significantly less breast symptoms and report a better
score for physical well-being. Significantly less patients in the 5-
fractions group experience a clinically relevant deterioration in
HRQoL of 10 points or more for physical functioning, social func-
tioning, fatigue, breast symptoms and physical well-being.4. Discussion
Two randomized controlled trials investigating an accelerated
RT schedule in 5 fractions have been published. In the FAST trial a
schedule of 5 fractions over 5 weeks, 1 fraction a week, was
compared with the former standard schedule of 25 fractions of
2 Gy. Tender or bright dermatitis with or without dry desquamation
2e8 weeks after RT was seen in 8.5% (28.5 Gy/5) vs. 35.5% (50 Gy/
25) and patchy moist desquamation and moderate edema in 5.2%
vs. 10.9% [10]. At 10 years follow-up, irradiation in 5 fractions was
comparable to 25 fractions regarding toxicity. Five fractions ofRT









67.4 (20.5) p ¼ 0.01 16 (15%) 30 (32%) p ¼ 0.005
86.8 (13.6) p ¼ 0.6 7 (7%) 23 (24%) p ¼ 0.0005e
83.0 (21.9) p ¼ 0.03 12 (11%) 29 (31%) p ¼ 0.0007e
59.9 (24.7) p ¼ 0.06 13 (12%) 20 (21%) p ¼ 0.09
35.2 (23.4) p ¼ 0.07 31 (30%) 47 (50%) p ¼ 0.003e
20.2 (21.7) p ¼ 0.2 23 (22%) 35 (37%) p ¼ 0.02
9.1 (14.0) p ¼ 0.6 18 (17%) 21 (22%) p ¼ 0.4
32.8 (19.9) p ¼ 0.001e 31 (30%) 56 (60%) p ¼ 0.0002e
67.4 (17.5) p ¼ 0.04 19 (18%) 30 (32%) p ¼ 0.02
27.4 (20.3) p ¼ 0.001e 28 (27%) 45 (48%) p ¼ 0.002e
p < 0,005).
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effects in the breast [9]. Later, in the FAST Forward trial, acceleration
to 5 fractions in 1 week was investigated: 5*5.2 Gy and 5*5.4 Gy
were compared to the current state of the art schedule of
15*2.67 Gy. Moderate dermatitis was seen in 27% vs. 47%, moderate
desquamation in 5% vs. 19% and moderate breast edema in 0% vs.
5%. Five-year results showed no statistically significant differences
in late toxicity, nor in locoregional or distant relapse, breast-related
events or all-cause mortality [15]. However, the application of these
5-fractions schedules in combination with a boost remains a topic
for debate. In the FAST trial, patients were all over 50 years old and
no boost was allowed. In the FAST-Forward trial, 25% of patients
received a sequential boost of 5e8 fractions of 2 Gy. However, it is
quite contradictory to treat the whole breast in fractions of over
5 Gy, while delivering the boost in fractions of 2 Gy. Moreover, 1e2
weeks of treatment are added which doubles the overall treatment
time and goes against the principle of acceleration. Omission of the
boost is justifiable in older patients since the benefit is limited and
the risk of toxicity is higher [22]. However, in some cases a boost is
still recommended. Use of a SIB allows to deliver a boost without
increasing the number of treatment fractions.
In the present sub-analysis of the YO-HAI5 study, acute toxicity
with a schedule of 5*5.7 Gy to the whole breast over 10e12 days is
evaluated. Over 90% of all patients received a SIB of 5*6.2 Gy. None
of the patients received lymph node irradiation (LNI). Physician-
assessment showed more than 20% less breast edema
(p ¼ 0.0007), dermatitis (p ¼ 0.003), pain (p ¼ 0.001) and fatigue
(p ¼ 0.0001) with this schedule than with a moderate hypo-
fractionation schedule of 15*2.67 Gy (SIB of 15*3.12Gy). The lower
rates of acute toxicity were not unexpected since these effects are
very sensitive to total dose, which is reduced using 5 fractions
compared to 15 fractions, and not to dose per fraction. The FAST-
Forward trial showed comparable results [15]. However, acute
toxicity might not predict for late toxicity, which is more dependent
on dose per fraction. In the FAST-Forward trial, late toxicity was
similar despite the marked difference in acute toxicity [23].
Despite the use of a SIB, moderate dermatitis and desquamation
(grade 2) were less frequent in our population than in the FAST
Forward trial. An explanation might be the 40 h treatment interval
between 2 fractions, but the same effect was observed for the 15-
fractions group making it more likely that the prone treatment
position [24] was responsible for the lower rates of toxicity than
observed in the FAST Forward trial [23]. However, comparison be-
tween both trials is challenging due to the different timing of
toxicity assessment. In the FAST Forward trial, acute toxicity was
measured up to 4 weeks after RT, while in our trial mean follow-up
time after completion of RT was 16.7 days ±6.0 days (16.6 days for
irradiation in 15 fractions, 16.7 days for 5 fractions). Toxicity
occurring after that time point could have beenmissed. However, in
the 15 fractions group of FAST-Forward, maximum tocixity rates
seemed to be reached at 2 weeks. This is consistent with our own
data published on WBI ± SIB in 15 fractions [24]. In the 5 fractions
group, most toxicity did not seem to aggravate beyond 2 weeks
after RT, except for some very rare grade 3 toxicity, appearing at 4
weeks after RT, possibly explained by the use of a sequentional
boost. Our data show that the frequency of toxicity was lower at the
last follow-up visit than at the end of RT, suggesting that maximum
toxicity occurred earlier than 2 weeks after RT. Patients were also
asked to contact us in case toxicity got worse after the last follow-
up visit.
Patient-reported outcomes showed that a deterioration in
global health status is less frequent in the groupwith less treatment
fractions (p ¼ 0.005). This is not surprising since the number of
patients experiencing a clinically relevant deterioration of fatigue,
of breast symptoms in general and of physical well-being were110reduced by respectively 20%, 30% and 21% in the 5-fractions group,
compared to the 15-fractions group (p ¼ 0.003, p ¼ 0.0002,
p ¼ 0.002). The interfering factors such as surgery, chemotherapy,
hormone therapy or RT technique were not significantly different
between both groups, so it can be assumed that this is the effect of
the acceleration, though other unknown variables can’t be
excluded.
Less treatment fractions also result in better social functioning:
20% less patients experience a disturbance of family life and/or
social activities in the 5-fractions group (p ¼ 0.0007). Some of the
physician-assessed toxicity endpoints are probably linked to items
of patient-reported outcome, e.g. physical functioning examines
the extent to which physical exertion is still possible, which is most
likely linked to fatigue. Breast symptoms and physical well-being
question pain, edema, skin problems, and how the breast feels
and its appearance. For linked items, both physician assessed and
patient reported outcome showed comparable results, i.e. superi-
ority of 5 fractions over 15 fractions.
In conclusion, physician-assessed toxicity is lower and patient-
reported outcome is better with an accelerated RT-schedule in 5
fractions over 10e12 days than with a hypofractionation schedule
of 15 fractions.References
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